Lead Product(s) : AAV1/SERCA2a
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Celladon
Deal Size : $5.4 million
Deal Type : Agreement
Novasep Signs €4.7m Biomanufacturing Deal with Biotech
Details : Through the agreement, Novasep will support Celladon’s plans to produce Mydicar, which is being evaluated in the mid-stage clinical trial for the treatment of heart failure.
Product Name : Mydicar
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 13, 2023
Lead Product(s) : AAV1/SERCA2a
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Celladon
Deal Size : $5.4 million
Deal Type : Agreement
Lead Product(s) : NAN-101
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bayer’s AskBio Initiates Phase II GenePHIT Trial in Congestive Heart Failure (CHF)
Details : NAN-101 (AB-1002) is a novel DUSP1 inhibitor which is currently being evaluated in phase 2 clinical trials for the treatment of congestive heart failure.
Product Name : NAN-101
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 01, 2024
Lead Product(s) : NAN-101
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Novo Nordisk
Deal Size : $1,110.0 million
Deal Type : Acquisition
Novo Nordisk to Acquire Cardior Pharmaceuticals, Enhancing Its Cardiovascular Pipeline
Details : Through the acquisition, Novo Nordisk expand its pipeline in cardiovascular disease by including Cardior’s lead compound CDR132L, currently in phase 2 clinical development for heart failure.
Product Name : CDR132L
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 25, 2024
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Novo Nordisk
Deal Size : $1,110.0 million
Deal Type : Acquisition
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.
Product Name : MK-0616
Product Type : Peptide
Upfront Cash : Inapplicable
February 21, 2023
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Asundexian
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bayer Receives U.S. FDA Fast Track Designation for Asundexian Stroke Program
Details : BAY2433334 (asundexian), is an oral inhibitor of Factor XIa, as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke, is currently in Phase II clinical trials in all three indications either as a standalone ...
Product Name : BAY 2433334
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2022
Lead Product(s) : Asundexian
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CDR132L is synthetic antisense oligonucleotide-based inhibitor directed against microRNA-132, that up-regulated in cardiac tissue of heart failure patients leading to expression of genes that are crucially involved in cardiac function thus leading to pat...
Product Name : CDR132L
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 20, 2022
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Asundexian
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from PACIFIC-AF trial demonstrated lower observed rates of ISTH major and clinically relevant non-major bleeding for BAY2433334 (asundexian), a FXIa inhibitor, compared with apixaban in patients with atrial fibrillation at risk of stroke.
Product Name : BAY 2433334
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2022
Lead Product(s) : Asundexian
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Relaxin-2 protein, human
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : CBL- Chemical and Biopharmaceutical Laboratories
Deal Size : Undisclosed
Deal Type : Partnership
Details : This cooperation agreement designates CBL as the exclusive manufacturing partner for synthetic human relaxin-2 (GMP and non-GMP) and Relaxera as the exclusive sales executive partner for relaxin.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
December 16, 2020
Lead Product(s) : Relaxin-2 protein, human
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : CBL- Chemical and Biopharmaceutical Laboratories
Deal Size : Undisclosed
Deal Type : Partnership